Pharmaceutical Industry Payments and Oncologists’ Selection of Targeted Cancer Therapies in Medicare Beneficiaries (2018)

Peer-Reviewed Study · Mitchell AP, Winn AN, Dusetzina SB · April 9, 2018

Mitchell AP et al., 2018-04-09: Research letter linking 2013 Open Payments to 2014 Part D prescribing for 354 metastatic kidney-cancer and 2,225 CML prescribers: any payment was associated with higher odds of prescribing that manufacturer's drug (OR 1.84 for mRCC, 1.31 for CML).

we found increased odds of prescribing a manufacturer’s drug among physicians receiving general payments only or either payment type

Results

Mitchell AP et al., 2018-04-09: Research letter linking 2013 Open Payments to 2014 Part D prescribing for 354 metastatic kidney-cancer and 2,225 CML prescribers: any payment was associated with higher odds of prescribing that manufacturer's drug (OR 1.84 for mRCC, 1.31 for CML). Funding: AHRQ postdoctoral traineeship 5T32 HS000032-28 (Mitchell) and a Royster Society of Fellows fellowship (Winn); 'Conflict of Interest Disclosures: None reported.' No industry funding; drugs studied are sorafenib/sunitinib/pazopanib and dasatinib/imatinib/nilotinib (makers not named in the letter). Comparator: physicians with no payments. CORRECTION: it is 2018 (JAMA Intern Med 178(6):854-856), not 'a 2014 study', and it is a 3-page research letter, not a full study; no 2014 JAMA Internal Medicine oncologist-payments paper exists in PubMed.